Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin’s lymphoma

Antibody drug conjugates (ADCs) can deliver potent drugs to cancer cells by employing the specificity of monoclonal antibodies (mAbs). ADCs have demonstrated significant anticancer activity and, in 2011, brentuximab vedotin has been approved by the FDA for the treatment of Hodgkin's and anaplas...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Jason, O’Donnell, Robert T., Abuhay, Mastewal, Tuscano, Joseph M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525602/
https://www.ncbi.nlm.nih.gov/pubmed/23264893
http://dx.doi.org/10.4161/onci.21815

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3525602/
https://www.ncbi.nlm.nih.gov/pubmed/23264893
http://dx.doi.org/10.4161/onci.21815

Ejemplares similares